Is Leqvio (Inclisiran) Safe While Breastfeeding?

The Short Answer: Breastfeeding and Leqvio Do Not Mix Right Now

The honest clinical answer is: no one knows whether inclisiran transfers into human breast milk in meaningful amounts, and no one knows what effect it would have on a nursing infant if it did. The FDA prescribing label for Leqvio states clearly that breastfeeding is not recommended during treatment and for a defined washout period afterward. That recommendation is not based on evidence of proven harm. It is based on the absence of any reassuring human data.

This distinction matters for you as a patient. "Not recommended" because we lack data is different from "contraindicated because we know it causes harm," but the practical advice is the same: choose a different lipid-lowering strategy while you are nursing.

Why the Data Gap Exists

Inclisiran received FDA approval in December 2021 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering. Clinical trials leading to approval, specifically ORION-9, ORION-10, and ORION-11, enrolled adults broadly but excluded pregnant and breastfeeding women. This is the same exclusion pattern that has left women with reproductive-age conditions chronically underrepresented in lipid-lowering trial data.

Women of childbearing age make up a substantial share of the HeFH population. Familial hypercholesterolemia affects approximately 1 in 250 people globally, meaning many women diagnosed with FH will face the postpartum period wanting to restart or intensify lipid-lowering therapy while also choosing to breastfeed. The evidence base to guide that decision simply does not exist for inclisiran yet.

What the FDA Label Actually Says

The Leqvio FDA prescribing information, Section 8.2 (Lactation) states that there are no data on the presence of inclisiran in human milk, the effects on the breastfed infant, or the effects on milk production.

The label language reads: "Because of the potential for serious adverse reactions in the breastfed infant, advise patients not to breastfeed during treatment with LEQVIO and for 5 months after the last dose."

Three pieces of that sentence require unpacking.

"Potential for serious adverse reactions"

This phrase reflects precautionary language standard for any novel molecule with no lactation data, not a documented toxicity signal in nursing infants. Inclisiran works by silencing the gene that encodes PCSK9 in hepatocytes. In theory, if an infant absorbed inclisiran, it could affect PCSK9 expression. Cholesterol is essential for infant neurodevelopment and myelination, so any drug that theoretically reduces cholesterol synthesis pathways in a rapidly growing infant brain warrants caution even without direct evidence of harm.

"5 months after the last dose"

This washout window is longer than inclisiran's plasma half-life of approximately 9 hours as noted in the FDA label pharmacokinetics section. It reflects the fact that inclisiran accumulates in liver tissue with a much longer functional duration. The drug is dosed only every six months precisely because of this prolonged tissue effect. The 5-month post-dose window is conservative and reflects regulatory caution about an incompletely characterized molecule in a vulnerable population.

Animal Data: What Rat Studies Tell Us (and Don't)

The FDA label notes that inclisiran was detected in the milk of lactating rats. LactMed, the NIH's drug and lactation database, confirms that animal data show low-level milk transfer, but emphasizes that rat milk transfer does not reliably predict human milk transfer for large, lipid-conjugated siRNA molecules. The clinical relevance to human lactation is unknown.

Inclisiran's molecular structure is relevant here. It is a synthetic small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which promotes hepatic uptake. The molecule is large (approximately 14.5 kDa), which would typically limit passive diffusion into breast milk. Larger molecules generally transfer into milk at lower rates than small lipophilic drugs. This is biologically plausible reassurance, but it has not been measured in lactating humans, so it remains extrapolation, not evidence.

Inclisiran in Pregnancy: An Equally Cautious Picture

If you are planning a pregnancy and are currently on inclisiran, or if you became pregnant while on treatment, this section is for you.

Human Pregnancy Data

There are no adequate or well-controlled studies of inclisiran in pregnant women. Section 8.1 of the FDA label states that animal reproductive toxicology studies showed no evidence of fetal harm at exposures up to four times the maximum recommended human dose. However, the absence of fetal harm in animals does not guarantee safety in humans, and inclisiran has not been assigned a traditional A/B/C/D/X pregnancy category under the older FDA system. Under the 2015 Pregnancy and Lactation Labeling Rule (PLLR), the label provides narrative data sections rather than letter grades.

The FDA label recommends discontinuing inclisiran as soon as pregnancy is recognized.

Why Cholesterol Management Still Matters in Pregnancy

Cholesterol biology in pregnancy is complex. Total cholesterol and LDL-C rise physiologically during the second and third trimesters, a process driven by estrogen and progesterone that supports fetal development and placental function. In women with HeFH, this physiological rise is superimposed on an already elevated baseline, and LDL-C levels in pregnant women with HeFH can exceed 300 mg/dL. Managing this is clinically challenging because statins, the most effective first-line agents, are contraindicated in pregnancy due to documented fetal harm.

The following table shows a practical framework for managing lipids across the postpartum and breastfeeding period in women with FH or ASCVD, organized by what is stopped, what can continue, and what can be started.

| Life Stage | Inclisiran | Statins | Bile Acid Sequestrants | PCSK9 mAbs (evolocumab, alirocumab) | |---|---|---|---|---| | Trying to conceive | Discontinue; plan washout | Discontinue | May continue (colesevelam) | Limited data; discuss with clinician | | Pregnant | Not recommended | Contraindicated | Safest option for LDL lowering | No adequate human data | | Breastfeeding | Not recommended; 5-month washout post-dose | Not recommended | Colesevelam preferred | No adequate human data | | Postpartum, not breastfeeding | May restart after discussion | May restart | Continue or stop per lipid goals | May restart |

Postpartum Cardiovascular Risk: Why This Matters More Than You Might Think

Postpartum is not a cardiovascular low-risk window. For women with pre-existing hypercholesterolemia or ASCVD, the postpartum period carries specific risks that make lipid management conversations urgent, not elective.

Preeclampsia, which affects approximately 5-8% of pregnancies in the United States, is an independent cardiovascular risk factor, roughly doubling a woman's lifetime risk of heart disease. Women with HeFH who also experienced preeclampsia exit pregnancy at higher cardiovascular risk than either condition alone would predict. Choosing between breastfeeding and resuming aggressive lipid-lowering therapy is a genuine clinical tension that deserves individualized counseling, not a generic pamphlet.

The decision to delay inclisiran restart is not trivial for a woman with very high LDL-C. If you breastfeed for 12 months and inclisiran requires a 5-month washout before restarting, you are looking at 17 months off the drug. For a woman with LDL-C persistently above 190 mg/dL and established plaque burden, that gap has cardiovascular consequences. This is a conversation to have directly with a lipidologist or preventive cardiologist alongside your OB or midwife.

Perimenopause and Cardiovascular Risk: A Connected Issue

Women in their 40s who are perimenopausal and also managing FH face an additional hormonal overlay. Estrogen decline during perimenopause accelerates LDL-C rises. The Menopause Society (formerly NAMS) acknowledges that LDL-C often increases during the menopausal transition, compounding existing FH-driven elevation. A perimenopausal woman with FH who is also breastfeeding a later-in-life baby sits at the intersection of three separate lipid-elevating physiological states. Her lipid management plan needs to account for all three.

Safer Lipid-Lowering Options During Breastfeeding

Several agents have a better-characterized safety profile during breastfeeding than inclisiran.

Bile Acid Sequestrants

Colesevelam and cholestyramine are not systemically absorbed. They work entirely within the gut by binding bile acids. Because neither drug reaches maternal circulation in meaningful amounts, milk transfer to the infant is not a concern. The FDA label for colesevelam does not contraindicate breastfeeding. These agents are not as potent as inclisiran or statins, typically reducing LDL-C by 15-18%, but they are the most conservative choice during lactation.

Omega-3 Fatty Acids

High-dose omega-3 preparations (icosapent ethyl, or combined EPA/DHA) are used for triglyceride management. The REDUCE-IT trial showed that icosapent ethyl 4 g/day reduced cardiovascular events in patients with elevated triglycerides on statins, but the population was not pregnant or breastfeeding. Omega-3s appear in breast milk and are considered beneficial for infant neurodevelopment at physiological concentrations. High-dose preparations during breastfeeding have not been specifically studied for safety at therapeutic doses.

Dietary and Lifestyle Modifications

The American College of Obstetricians and Gynecologists supports dietary saturated fat reduction and increased physical activity as first-line adjuncts during the postpartum period. For women with HeFH whose LDL-C elevation is genetic rather than diet-driven, lifestyle measures alone are insufficient to reach goal, but they reduce the gap that pharmacological therapy needs to close.

Who This Decision Matters Most For (Life-Stage Guide)

Postpartum Women With Familial Hypercholesterolemia

You are the primary audience for this article. If you have HeFH, your LDL-C was probably above 190 mg/dL before pregnancy and rose further during gestation. You may have been on inclisiran before becoming pregnant and stopped it per your clinician's advice. Your question now is whether you can restart while nursing. The answer is: not recommended per current FDA guidance. Colesevelam is the most defensible choice during active breastfeeding if LDL lowering cannot wait.

Women With Established ASCVD Who Are Breastfeeding

If you had a myocardial infarction, stroke, or coronary intervention before or during pregnancy, your cardiovascular risk profile is high. The delay in restarting potent LDL-C lowering is a real tradeoff. ACOG's guidance on cardiovascular disease in pregnancy does not specifically address inclisiran but endorses individualized multidisciplinary care for high-risk postpartum cardiac patients. A shared decision-making conversation with cardiology and your lactation provider is warranted.

Reproductive-Age Women Who Are Planning Pregnancy

If you are currently on inclisiran and planning to conceive, discuss timing with your clinician. Given inclisiran's 5-month recommended washout from the last dose, and a dosing interval of every 6 months, you would typically stop after your second or third dose and allow washout before active conception attempts. ASRM's committee opinion on preconception care recommends reviewing all long-acting medications before conception.

Women in Perimenopause With Newly Diagnosed High LDL-C

If you are perimenopausal and your LDL-C has risen significantly in the past two to three years, inclisiran may be on the table as a newer agent. Breastfeeding is not typically active during perimenopause, but if you are in the unusual situation of nursing a child while also experiencing menopausal symptoms (not rare for women in their mid-to-late 40s), the same guidance applies: inclisiran is not recommended during lactation.

What We Know About Inclisiran's Pharmacology and Why It Matters for Lactation Risk Assessment

Inclisiran's mechanism is unlike statins or PCSK9 monoclonal antibodies (evolocumab, alirocumab). Understanding this distinction helps explain the specific uncertainty around milk transfer.

Inclisiran is a siRNA molecule that is taken up predominantly by hepatocytes via the asialoglycoprotein receptor (ASGPR), enabled by its GalNAc conjugate. Once inside hepatocytes, the antisense strand binds to PCSK9 mRNA and triggers its degradation by the RNA-induced silencing complex (RISC). In the ORION-1 trial, a single dose of inclisiran 300 mg produced LDL-C reductions of up to 51% sustained at 180 days.

The persistence of effect is the key pharmacological feature for lactation counseling. A single dose given on day 1 of postpartum to a breastfeeding mother would, in theory, continue influencing hepatic PCSK9 expression for months. Even if milk transfer is low, the duration of potential infant exposure matters because of inclisiran's long tissue half-life, not its short plasma half-life.

This is mechanistically distinct from a drug dosed daily, where cessation of the drug leads to rapid clearance. With inclisiran, stopping the dosing schedule does not mean the drug stops working. The 5-month post-dose washout recommendation reflects this.

Questions to Ask Your Clinician Before Making a Decision

Concrete questions that will move the conversation forward in an appointment:

• What is my current LDL-C, and how far is it from my goal?
• What is my 10-year ASCVD risk score with my current LDL-C untreated?
• How long do I plan to breastfeed, and can a bile acid sequestrant bridge me safely?
• Are there any case registry programs enrolling breastfeeding women on lipid-lowering agents that might generate the safety data this field needs?
• If I choose to breastfeed for 6 months and then restart inclisiran, what is my estimated cumulative LDL-C exposure during that gap?

Your cardiologist, lipidologist, and OB or midwife should all be part of this conversation. Telehealth can support the coordination, but the decision needs specific numbers, not general guidance.

A Note on the Evidence Gap for Women

This article would not need several sections acknowledging uncertainty if women of childbearing age had been included in inclisiran trials. They were not. This is the same gap that existed for statins for decades, leading to a reflexive "contraindicate everything in pregnancy and lactation" approach that sometimes deprives women of therapies that would actually be safe.

A 2022 analysis in JAMA Internal Medicine documented that pregnant and lactating women remain systematically excluded from cardiovascular drug trials, leaving clinicians to extrapolate from animal data and pharmacological plausibility. The authors called for dedicated post-marketing studies in reproductive-age women for approved cardiovascular drugs. Inclisiran is exactly the type of drug this recommendation targets.

Novartis, as post-marketing commitment to the FDA, may be required to generate reproductive safety data over time. Until that data exists, the clinical recommendation remains conservative: avoid inclisiran during breastfeeding and use the washout period the label specifies.